BharatNotes What is Stem Cells?
Stem cells are the body's "master cells" — unspecialised cells with two defining abilities recognised by the US National Institutes of Health: self-renewal (dividing for long periods to make copies of themselves) and differentiation (maturing into specialised cell types such as neurons, blood, muscle or skin). This dual capacity makes them the raw material from which every tissue is built and repaired.
Types by Potency
Stem cells are classified along a "potency" continuum — the more cell types a cell can become, the higher its potency.
| Type | What it can form | Example |
|---|---|---|
| Totipotent | An entire organism (all cell types + placenta) | Zygote / early embryo |
| Pluripotent | All three germ layers (ecto-, meso-, endoderm) | Embryonic stem cells; iPSCs |
| Multipotent | Several related cell types of one tissue | Haematopoietic (bone-marrow) stem cells |
| Unipotent | A single mature cell type | Certain skin / muscle progenitors |
By source, the major categories are embryonic stem cells (pluripotent, from the early embryo), adult/somatic stem cells (e.g. bone marrow, more limited potency), and induced pluripotent stem cells (iPSCs).
The iPSC Breakthrough
In 2006, Shinya Yamanaka and Kazutoshi Takahashi showed that introducing four transcription-factor genes — Oct4, Sox2, Klf4 and c-Myc ("Yamanaka factors") — could reprogramme ordinary adult cells back into a pluripotent state. Because iPSCs are patient-derived, they sidestep the ethical concerns of embryonic cells and lower the risk of immune rejection. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon (source: NobelPrize.org).
Clinical Status
The longest-established, proven application is haematopoietic stem-cell (bone-marrow) transplantation for leukaemias, lymphomas and aplastic anaemia. Approved cell products remain limited but are expanding: the US FDA approved Ryoncil (remestemcel-L) on 18 December 2024 — the first mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in children (FDA press announcement, Dec 2024). Most other "stem-cell therapies" advertised commercially remain unproven.
India and Regulation
India's framework is the National Guidelines for Stem Cell Research (2017), jointly issued by the Department of Biotechnology (DBT) and the Indian Council of Medical Research (ICMR) on 11 October 2017. A core rule: no stem-cell administration to humans is permissible outside an approved clinical trial — all clinical use must be backed by trials proving safety and efficacy. Oversight runs through the National Apex Committee (NAC-SCRT) and Institutional Committees (IC-SCR). A noted weakness is that the guidelines lack statutory enforcement powers, allowing unproven therapies to persist (DBT, 2017).
UPSC Angle
Stem cells sit at the crossroads of GS3 (biotechnology, regenerative medicine, health technology) and GS4 (bioethics of embryonic research and unproven therapies). Aspirants should be able to distinguish the potency types, explain iPSCs and the Yamanaka discovery, and critique India's regulatory gaps — a foundation concept underpinning broader biotechnology questions.
